Dossier SM/TX — SaaS & MedTech

Software still has to earn clinical trust.

Dan's current focus sits at the intersection of SaaS and medicine — where a platform's technical merits mean little until sales, access, and adoption actually put it in front of patients and members. As VP of Sales, Healthcare at DaysToHappy, he leads go-to-market for an AI-powered biometric health and engagement platform built on the company's HealthScan technology, carrying the same discipline he's applied to health-tech sales for years: read the buyer, respect the regulation, and close on substance.

That discipline shows up in the deals that actually closed, not just the ones pursued.

Dossier Summary

Sector
Digital health, biometric engagement, telemedicine, ed-tech
Current
VP of Sales, Healthcare — DaysToHappy
Platform
HealthScan — AI biometric health & engagement
Motion
Enterprise & healthcare-channel sales

Closed Wins

Deals that actually closed

DaysToHappyVP of Sales, Healthcare

Leading healthcare go-to-market for an AI-powered biometric health and engagement platform, built on the company's HealthScan technology — bringing enterprise health-tech sales discipline to a fast-moving product organization.

Salud Health USACareClix — 28-Country Telemedicine Footprint

Grew the CareClix telemedicine platform into a 28-country footprint, closing the international distribution deals that took a single-market product global.

Salud Health USASecured Communications — Hospital Santa Fe de Bogotá

Closed the sale of Secured Communications software into Hospital Santa Fe de Bogotá, placing a U.S. health-tech platform inside a major Latin American hospital system.

AloeVRBehavioral Health VR — Nevada Charter School District

Closed the placement of AloeVR's Behavioral Health VR platform into a Nevada charter school district, driving a 350% increase in revenue per student.

1800MDTelehealth Kiosk — Indian Nations

Developed a telehealth kiosk concept with 1800MD for deployment across Indian Nations. The project was fully scoped but ultimately did not move forward — included here as part of the full record, not just the wins.

"The technology is rarely the hard part. The hard part is getting a regulated buyer, in an unfamiliar market, to say yes."

Related Dossiers